BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/29/2024 7:44:38 AM | Browse: 380 | Download: 1214
 |
Received |
|
2024-04-20 10:36 |
|
Peer-Review Started |
|
2024-04-20 10:36 |
|
First Decision by Editorial Office Director |
|
2024-05-28 07:03 |
|
Return for Revision |
|
2024-05-28 07:03 |
|
Revised |
|
2024-06-23 20:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-08-02 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-08-02 09:07 |
|
Articles in Press |
|
2024-08-02 09:07 |
|
Edit the Manuscript by Language Editor |
|
2024-08-07 23:06 |
|
Typeset the Manuscript |
|
2024-08-19 00:54 |
|
Publish the Manuscript Online |
|
2024-09-29 07:44 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell & Tissue Engineering |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Serdar Kabatas, Erdinç Civelek, Eyüp Can Savrunlu, Umut Karaaslan, Özlem Yıldız and Erdal Karaöz |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Serdar Kabatas, MD, Full Professor, Department of Neurosurgery, University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi 616. Sokak No. 10, Gaziosmanpaşa, Istanbul 34255, Türkiye. kabatasserdar@hotmail.com |
| Key Words |
Autism spectrum disorder; Neurorehabilitation; Stem cell transplantation; Wharton jelly mesenchymal cells |
| Core Tip |
According to the data of the World Health Organization, Autism Spectrum Disorder (ASD) is observed in approximately one in every hundred children. Recent studies have revealed that immune factors and inflammation are effective in the development of ASD. In this study, we applied 6 doses of Wharton's jelly-derived mesenchymal stem cell therapy to a 4-year-old patient diagnosed with autism spectrum disorder. After the applications, we observed the patient for 2 years. We did not encounter any serious side effects. According to Childhood Autism Rating Scale values and Denver II Developmental Screening Test values, we detected significant improvements. |
| Publish Date |
2024-09-29 07:44 |
| Citation |
Kabatas S, Civelek E, Savrunlu EC, Karaaslan U, Yıldız Ö, Karaöz E. Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. World J Methodol 2025; 15(1): 95857
|
| URL |
https://www.wjgnet.com/2222-0682/full/v15/i1/95857.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v15.i1.95857 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
